

18 September 2023

Respiri Early Redemption of Convertible Note through a \$1.3m in a private placement

Highlights:

- Unsolicited approach by High Net Worth investors raises \$1.3M to extinguish existing convertible note debt and provide additional working capital.
- Placement was above market price (Last Share Price 3.2c)
- Strong interest from existing and new investors demonstrates support for Respiri's strategic direction and progress in the USA market.
- Incoming shareholder, Mr. Ian Parkin praises Respiri's drive to solve business challenges and innovative approach to accessing opportunities in the US market.

Respiri Limited (ASX:RSH; OTCQB:RSHUF) ("Respiri" or the "Company"), an eHealth SaaS Company supporting respiratory healthcare management and remote patient monitoring, is pleased to announce that the Company has completed a A\$1.3m private placement of new ordinary shares and attaching options to sophisticated investors that are not related parties of the of the Company.

Proceeds from the private placement will be used to payout 100% of the Obsidian convertible note (settlement sum of \$410,000), with additional funds over and above this for further USA working capital to continue to drive accelerated Remote Patient Monitoring patient acquisition with existing clients and finalising and preparing for anticipated significant contracted clients which the company hopes to announce in the coming months.

The placement terms are consistent with the recent Share Purchase Plan and comprises 38,235,294 new ordinary shares at an issue price of A\$0.034 per share, with one (1) free attaching listed Option (ASX code RSHO) for every two (2) shares subscribed for, exercisable at A\$0.065 and expiring 30 June 2025.

The private placement had strong interest from both existing and new investors, which continues to endorse the strategic direction that Respiri has taken, the significant progress its team has made in the USA and the anticipated milestones the Company hopes to achieve before the end of CY 2023 and beyond which is expected to drive a monthly cash flow positive outcome in H2, 2024. The Company welcomes the additional support of both incoming new and current shareholders.

Incoming new shareholder, **Mr Ian Parkin**, founding partner of Australian employee off-shoring organisation **Yempo**, who has partnered with Respiri in setting up and administrating the successful **Digital Innovation Excellence Hub in the Philippines**, said, "Yempo has partnered closely with Respiri over the last two years, supporting the team as they built out their Tier 1 engineering capability in the Philippines. Throughout this, I've been impressed with Respiri's drive to solve business challenges without compromising capability or quality. More recently, the acquisition of Access Telehealth and Respiri's US go-to-market strategy has shown great innovation regarding accessing opportunities in the US market. These are exciting times for Respiri, and it's fantastic that we can further support them in these endeavours through investment".

Nicholas Smedley, Respiri Chairman, said, "An overwhelming show of support for what the Respiri Team is achieving and what it plans to deliver from both new and existing investors. This placement further underlines the market endorsement of the Company's strategy to drive recurring revenue from the attractive US remote patient monitoring market. Also, it allows the Company to remove the convertible note from our balance sheet, simplifying our capital structure, which is what our shareholders and the market wanted."

"Now we continue to do what we have done, deliver RPM patient numbers on existing contracts and secure significant new clients. The future looks very promising for us and our shareholders".

-ENDS-

For further information, investors and media, please contact:

Mr Marjan Mikel
CEO & Managing Director
Respiri Limited
P: +61 408 462 873
E: marjan@respiri.co

Mr Nicholas Smedley
Executive Chairman
Respiri Limited
P: +61 447 074 160
E: nicholas@respiri.co

This ASX announcement has been authorised for release by the Board of Directors of Respiri Limited.

About Respiri Limited

Respiri is an e-Health SaaS company supporting respiratory health management and Remote Patient Monitoring services. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. wheezo®, Respiri's innovative technology, comprises an eHealth app combined with a simple, easy to use, handheld device. wheezo® is the first smart device to help improve asthma management by monitoring wheeze and documenting symptoms, signs, triggers, weather conditions and medication use. The asthma management platform also facilitates the sharing of data with caregivers, physicians and other health care professionals.

Respiri's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respiri Limited's operations are based in Melbourne, Australia and in New York, USA.

For additional information about Respiri and its products, please visit www.respiri.co

About wheezo®

Developed in Australia, with the support of respiratory specialists and other healthcare professionals, the innovative wheezo® device analyses breath sounds for wheeze, and the eHealth App assists patients with managing their asthma by tracking symptoms, triggers, medication use and geo-specific weather conditions. The platform has been designed to extend asthma management beyond the clinic and make it easy to share information with doctors and make appropriate adjustments to asthma action plans. Better active management may lead to better outcomes and improved quality of life for the asthma patient.

For further information about wheezo®, follow the online link <https://wheezo.com>

wheezo® is a registered trademark of Respiri Limited.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Respiri current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Respiri only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.